Enlivex Ltd. (Bioblast Pharma Ltd.) Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Bioblast Pharma Ltd. (also referenced as Enlivex Ltd.) on March 18, 2019, covering the month of March 2019. The filing reports on the results of an Extraordinary General Meeting of Shareholders held on March 17, 2019.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions rather than financial performance.
Material Changes
At the Extraordinary General Meeting, shareholders approved the agenda item as originally proposed. This item was previously described in Exhibits 99.1 and 99.2 of a Form 6-K submitted on February 19, 2019. The filing does not detail the specific nature of the approved agenda item within this text.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It serves solely to confirm the shareholder approval of the previously disclosed agenda item.
Key Facts for Investor Verification
- Shareholders approved the agenda item proposed in the February 19, 2019 Form 6-K (Exhibits 99.1 and 99.2).
- The meeting took place on March 17, 2019.
- Dr. Dalia Megiddo signed the report as Interim Chief Executive Officer.
- The report is incorporated by reference into registration statements on Form S-8 (File Nos. 333-203114 and 333-210459).